# A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age

> **NCT00952705** · PHASE3 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 1800 (actual)

## Conditions studied

- Healthy or Stable Underlying Chronic Medical Condition

## Interventions

- **BIOLOGICAL:** Q/LAIV-BFS (MEDI8662)
- **BIOLOGICAL:** FluMist/B/Yamagata
- **BIOLOGICAL:** FluMist/B/Victoria

## Key facts

- **NCT ID:** NCT00952705
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-01
- **Final completion:** 2010-03
- **Target enrollment:** 1800 (ACTUAL)
- **Last updated:** 2018-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00952705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00952705, "A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00952705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*